Rick Gonzalez, AbbVie CEO (Chris Kleponis/picture-alliance/dpa/AP Images)
April 27, 2023 01:47 PM EDTUpdated April 28, 07:38 AM
Pharma

Up­dat­ed: Ab­b­Vie ax­es two can­di­dates as com­pa­ny rev­enue drops near­ly 10%

Paul Schloesser

Associate Editor

Ab­b­Vie is dump­ing two can­di­dates in cys­tic fi­bro­sis and Crohn’s dis­ease at the same time the drug­mak­er is grap­pling with dwin­dling sales of Hu­mi­ra, long …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Mi­crosoft-backed Enve­da rais­es $130M for drugs in I&I, obe­si­ty and oth­er ar­eas

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

As­traZeneca culls Phase 2 opi­oid use dis­or­der drug

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times